Pulmonx Corporation (LUNG)
Market Cap | 245.32M |
Revenue (ttm) | 72.99M |
Net Income (ttm) | -58.73M |
Shares Out | 38.82M |
EPS (ttm) | -1.54 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 156,726 |
Open | 6.27 |
Previous Close | 6.24 |
Day's Range | 6.21 - 6.37 |
52-Week Range | 5.67 - 14.84 |
Beta | 0.65 |
Analysts | Strong Buy |
Price Target | 15.25 (+141.3%) |
Earnings Date | Jul 31, 2024 |
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitat... [Read more]
Financial Performance
In 2023, Pulmonx's revenue was $68.68 million, an increase of 27.98% compared to the previous year's $53.66 million. Losses were -$60.84 million, 3.26% more than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LUNG stock is "Strong Buy." The 12-month stock price forecast is $15.25, which is an increase of 141.30% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/k/e/press11-2413349.jpg)
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announc...
![](https://cdn.snapi.dev/images/v1/y/0/press7-2404165.jpg)
Pulmonx Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reporte...
![](https://cdn.snapi.dev/images/v1/7/e/conf20-2366129.jpg)
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will...
![](https://cdn.snapi.dev/images/v1/3/u/press4-2353041.jpg)
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today annou...
![](https://cdn.snapi.dev/images/v1/w/4/press7-2293306.jpg)
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD...
![](https://cdn.snapi.dev/images/v1/b/s/press3-2286974.jpg)
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
![](https://cdn.snapi.dev/images/v1/9/m/press1-2286970.jpg)
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
![](https://cdn.snapi.dev/images/v1/n/c/conf12-2265516.jpg)
Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
![](https://cdn.snapi.dev/images/v1/t/p/conf13-2160229.jpg)
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...
![](https://cdn.snapi.dev/images/v1/o/q/conf11-2131506.jpg)
Pulmonx to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...
![](https://cdn.snapi.dev/images/v1/r/z/press13-2128905.jpg)
Pulmonx Reports Record Third Quarter 2023 Financial Results
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
![](https://cdn.snapi.dev/images/v1/s/g/conf15-2105398.jpg)
Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
![](https://cdn.snapi.dev/images/v1/1/u/press8-2097652.jpg)
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
![](https://cdn.snapi.dev/images/v1/1/3/press20-2002447.jpg)
Pulmonx Reports Second Quarter 2023 Financial Results
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
![](https://cdn.snapi.dev/images/v1/q/s/conf11-1990162.jpg)
Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the co...
![](https://cdn.snapi.dev/images/v1/s/i/conf15-1973640.jpg)
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
REDWOOD CITY, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
![](https://cdn.snapi.dev/images/v1/8/x/press6-1866728.jpg)
Pulmonx Reports First Quarter 2023 Financial Results
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reporte...
![](https://cdn.snapi.dev/images/v1/l/q/conf3-1853368.jpg)
Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference
REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the co...
![](https://cdn.snapi.dev/images/v1/y/l/conf13-1842396.jpg)
Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial...
![](https://cdn.snapi.dev/images/v1/w/k/press17-1765985.jpg)
Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
![](https://cdn.snapi.dev/images/v1/t/l/conf15-1758537.jpg)
Pulmonx to Present at the Citi 2023 Healthcare Conference
REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...
![](https://cdn.snapi.dev/images/v1/z/t/conf11-1745329.jpg)
Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
![](https://cdn.snapi.dev/images/v1/1/0/press11-1675885.jpg)
American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Asso...
![](https://cdn.snapi.dev/images/v1/1/o/press7-1656088.jpg)
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japa...
![](https://cdn.snapi.dev/images/v1/x/n/conf3-1640686.jpg)
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the co...